Below you'll find a list of all posts that have been tagged as “life sciences”
In unpredictable markets, resilience isn’t optional, it’s essential. This piece explores how economic and regulatory shocks test corporate strategies and why embedding agility and cross-functional coordination into CI frameworks empowers companies to weather turbulence and stay nimble.
Background A leading medical aesthetics company sought to prepare for a significant competitive disruption: the anticipated entry of a rival global manufacturer into the U.S. market. The client understood that this competitor’s entry would be accompanied by assertive marketing, differentiated product claims, and a well-funded commercial strategy, threatening to erode its market share and customer loyalty. To defend its position …
The Situation A global medical device manufacturer sought to deepen its competitive intelligence in the gastrointestinal (GI) space. As market dynamics evolved rapidly, driven by innovation in imaging systems, increased digitization, and shifting regulatory environments, the client aimed to benchmark its own R&D and sales strategies against key competitors in the GI medical device category. They needed to understand: How …
In a high-stakes, fast-moving pharma landscape, the best competitive intelligence partners do more than deliver data, they drive strategy. This post outlines eight essential traits that set leading CI firms apart, based on real-world buyer insights and evolving industry demands.
At the Pharma CI Conference (Sept 25–26, 2024), leaders discussed how shifts like the IRA’s impact on drug pricing, AI in R&D, and shifting regulatory regimes are reshaping life sciences CI. Read this summary to grasp the conference’s breakout trends and strategic implications.
Through analysis of IO clinical trials (2018–2022), we reveal how top‑20 pharma concentrate on mAb trials globally, while smaller firms explore innovative modalities like BsAb and CAR‑T, and how China is emerging as an IO hub. These patterns offer strategic cues for reshaping your trial portfolio and R&D focus.
This first article, part of a three-post series, focusses on need for such a meeting and underlines the impact of accelerated approvals in the field of Oncology.
The COVID-19 pandemic has had a very strong impact on all global economies across multiple sectors. Its impact on the US Pharma industry was significant in the first quarter, causing most companies to adjust and realign their businesses in response to the outbreak. The pandemic not only had a direct impact on Q1 revenues, but also affected overall drug development …
Before COVID-19 transpired executives were concerned with their strategic assumptions and the results of getting them wrong. A February 2020 Gartner study cited lack of confidence in strategic assumptions as the leading corporate risk among senior executives across a diverse set of industries and global geographies in Q4 2019. A strategic assumption can be defined as the unstated belief that something is likely to occur to enable an achievable strategic goal. Depending on the …
The COVID-19 outbreak generated widespread concern over how pharmaceutical, biotechnology, and medtech companies would cope with stringent national and regional lockdowns. Financial results from Q1 provide the first indicator of how this public health crisis will impact this industry and what the future may hold. By early May, earnings for most of the significant players in the pharma industry had been announced, …
